Opyl Limited Expands Globally with Xco JV

Opyl Ltd. (AU:OPL) has released an update.

Opyl Limited, an AI-focused clinical trial design company, has announced a joint venture with the US and UK-based Xco consortium to market and sell its TrialKey products in Europe, the Middle East, Africa, and North America. The deal includes a due diligence period, a cash payment to Opyl for licensing, a planned capital raise for the JV, and a revenue-sharing agreement. Executive Chairman Saurabh Jain views the partnership as a strategic move to scale the company’s global presence and drive growth.

For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.